Notable industry trends throughout 2024 include the continued growth of the specialty market. Across the industry, specialty medications now account for an estimated 54% of spending which has been driven mainly by…

Amneal announced FDA approval of exenatide 5mcg/1.2mL and 10mcg/2.4mL prefilled pen injection on November 21, 2024. This generic references Byetta® (exenatide – AstraZeneca), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated…

The Inflation Reduction Act (IRA) of 2022 created the Medicare Drug Price Negotiation (DPN) Program in an effort to decrease the of cost of medications through Medicare. As a result of this program, the Centers for Medicare & Medicaid Services (CMS), select…

On October 2, 2024, Mylan Pharmaceuticals and Novo Nordisk reached a confidential settlement agreement regarding the launch date of generic versions of Ozempic (semaglutide). Although the agreement remains confidential…

The 2022 Inflation Reduction Act (IRA) makes significant changes to the Medicare Part D standard benefit, including capping annual enrollee out-of-pocket spending. The new provisions are being implemented gradually through 2025. While some changes…